Cyclic amide derivative

1. A compound of formula (1), or a pharmaceutically acceptable salt thereof:

[wherein A is C 6-10 arylene, or 5- or 6-membered monocyclic heteroarylene selected from the group of the following group:

R 1a , R 1b and R 1c are each independently,

(1) hydrogen atom,

(2) deuterium atom,

(3) halogen atom,

(4) cyano group,

(5) C 1-4 alkyl group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s),

(b) C 1-4 alkoxy (in which the group may be optionally substituted by 1 to 3 halogen atom(s)),

(c) C 3-6 cycloalkyl,

(d) C 3-6 cycloalkoxy, or

(e) heterocycle),

(6) C 1-4 alkoxy group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s),

(b) C 1-4 alkoxy (in which the group may be optionally substituted by 1 to 3 halogen atom(s)),

(c) C 3-6 cycloalkyl, or

(d) C 3-6 cycloalkoxy),

(7) C 3-6 cycloalkyl group,

(8) C 3-6 cycloalkoxy group,

(9) heterocyclic oxy group, or

(10) C 7-16 aralkyloxy group;

R 2 is optionally substituted C 6-10 aryl group, optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl group, optionally substituted C 7-16 aralkyl group, optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl-C 1-6 alkyl group, optionally substituted heterocycle group, or C 1-6 alkyl group (in which the alkyl group may be optionally substituted by optionally substituted C 6-10 aryloxy);

m is 0 or 1;

n is an integer of 0 to 2.]

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is 1,3-phenylene, or 1,4-phenylene.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein A is 1,4-phenylene.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is 5- or 6-membered monocyclic heteroarylene selected from the group of the following group:

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein 5- or 6-membered monocyclic heteroarylene in A is selected from the group of the following group:

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1a is

(1) halogen atom,

(2) cyano group,

(3) C 1-4 alkyl group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s), or

(b) C 1-4 alkoxy (in which the group may be optionally substituted by 1 to 3 halogen atom(s))),

(4) C 1-4 alkoxy group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s), or

(b) C 1-4 alkoxy (in which the group may be optionally substituted by 1 to 3 halogen atom(s))),

(5) C 3-6 cycloalkyl group,

(6) C 3-6 cycloalkoxy group,

(7) heterocyclic oxy group, or

(8) C 7-16 aralkyloxy group.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 1a is C 1-4 alkyl group which may be optionally substituted by C 1-4 alkoxy.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1b is

(1) hydrogen atom,

(2) C 1-4 alkyl group,

(3) C 1-4 alkoxy group, or

(4) C 3-6 cycloalkyl group.

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 1b is hydrogen atom.

10. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 1b is C 1-4 alkyl group, or C 3-6 cycloalkyl group.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1c is hydrogen atom, C 1-4 alkyl group, or C 3-6 cycloalkyl group.

12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein R 1c is hydrogen atom.

13. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein R 1c is C 1-4 alkyl group.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein substituent(s) of optionally substituted C 6-10 aryl group, optionally substituted 5- or 6-membered monocyclic heteroaryl group, optionally substituted C 7-16 aralkyl group, optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl-C 1-6 alkyl group and optionally substituted heterocycle group in R 2 is

(1) halogen atom,

(2) cyano group,

(3) C 1-4 alkyl group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s),

(b) C 1-4 alkoxy (in which the group may be optionally substituted by 1 to 3 halogen atom(s)),

(c) C 3-6 cycloalkyl,

(d) C 3-6 cycloalkoxy, or

(e) heterocycle),

(4) C 1-4 alkoxy group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s),

(b) C 1-4 alkoxy (in which the group may be optionally substituted by 1 to 3 halogen atom(s)),

(c) C 3-6 cycloalkyl, or

(d) C 3-6 cycloalkoxy),

(5) C 3-6 cycloalkyl group,

(6) C 3-6 cycloalkoxy group (in which the group may be optionally substituted by C 1-4 alkoxy),

(7) heterocycle group,

(8) 5- to 7-membered cyclic amino group,

(9) C 1-4 alkylthio group, or

(10) C 1-4 alkylsulfonyl group.

15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof, wherein R 2 is

(1) C 6-10 aryl group (in which the group may be optionally substituted by the same or different 1 to 5 group(s) selected from the group consisting of

(a) halogen atom,

(b) cyano,

(c) C 1-4 alkyl (in which the alkyl may be optionally substituted by

1 to 3 halogen atom(s), or

C 1-4 alkoxy),

(d) C 1-4 alkoxy (in which the alkoxy may be optionally substituted by

1 to 3 halogen atom(s), or

C 1-4 alkoxy),

(e) C 3-6 cycloalkyl group, and

(f) 5- to 7-membered cyclic amino group),

(2) 5- or 6-membered monocyclic heteroaryl group (in which the group may be optionally substituted by the same or different group(s) selected from the group consisting of

(a) halogen atom,

(b) C 1-4 alkyl (in which the alkyl may be optionally substituted by

1 to 3 halogen atom(s), or

C 1-4 alkoxy), and

(c) C 1-4 alkoxy group (in which the alkoxy may be optionally substituted by

1 to 3 halogen atom(s), or

C 3-6 cycloalkyl)),

(3) C 7-14 aralkyl group (in which the group may be optionally substituted by the same or different 1 to 5 group(s) selected from the group consisting of

(a) halogen atom,

(b) C 1-4 alkyl (in which the alkyl may be optionally substituted by

1 to 3 halogen atom(s), or

C 1-4 alkoxy),

(c) C 1-4 alkoxy (in which the alkoxy may be optionally substituted by

1 to 3 halogen atom(s), or

C 1-4 alkoxy),

(d) C 3-6 cycloalkyl, and

(e) 5- to 7-membered cyclic amino), or

(4) saturated heterocycle group.

16. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 2 is C 6-10 aryl group, or 5- or 6-membered monocyclic heteroaryl group (in which the groups may be optionally substituted by the same or different 1 to 3 group(s) selected from the group consisting of

(a) halogen atom,

(b) C 1-4 alkyl (in which the alkyl may be optionally substituted by 1 to 3 halogen atom(s)), and

(c) C 1-4 alkoxy (in which the alkoxy may be optionally substituted by 1 to 3 halogen atom(s))).

17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein 5- or 6-membered monocyclic heteroaryl group in R 2 is one group selected from the following group:

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein a compound of formula (1) is a compound of the following formula:

19. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein a compound of formula (1) is a compound of the following formula:

20. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein a compound of formula (1) is a compound of the following formula:

21. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein a compound of formula (1) is a compound of the following formula:

22. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein R 1a is

(1) halogen atom,

(2) cyano group,

(3) C 1-4 alkyl group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s),

(b) C 1-4 alkoxy,

(c) C 3-6 cycloalkyl,

(d) C 3-6 cycloalkoxy, or

(e) heterocycle),

(4) C 1-4 alkoxy group (in which the group may be optionally substituted by 1 to 3 halogen atom(s)), or

(5) C 3-6 cycloalkyl group;

R 1b is hydrogen atom, or C 1-4 alkyl group;

R 1c is C 1-4 alkyl group, or C 3-6 cycloalkyl group.

23. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 1a is

(1) halogen atom,

(2) C 1-4 alkyl group (in which the group may be optionally substituted by

(a) 1 to 3 halogen atom(s), or

(b) C 1-4 alkoxy),

(3) C 3-6 cycloalkyl group, or

(4) C 1-4 alkoxy group (in which the group may be optionally substituted by 1 to 3 halogen atom(s)).

24. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 1b is hydrogen atom.

25. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 1c is C 1-4 alkyl group.

26. The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein R 1c is methyl group.

27. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the following compound group:

5-benzoyl-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-5-(2-methylbenzoyl)-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-5-(3-methylbenzoyl)-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-5-(4-methylbenzoyl)-1H-pyrrole-2-carboxamide,

5-(4-chlorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-5-(2-methoxybenzoyl)-1,3-dimethyl-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-5-(3-methoxybenzoyl)-1,3-dimethyl-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-5-(4-methoxybenzoyl)-1,3-dimethyl-1H-pyrrole-2-carboxamide,

3-chloro-5-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-benzoyl-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(3-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-benzoyl-N-[(E)-5-hydroxyadamantan-2-yl]-3-(methoxymethyl)-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-5-(3-methoxybenzoyl)-1-methyl-1H-pyrrole-2-carboxamide,

N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-5-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1H-pyrrole-2-carboxamide,

5-(2,4-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-benzoyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-3-propyl-1H-pyrrole-2-carboxamide,

5-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-3-propyl-1H-pyrrole-2-carboxamide,

5-(3-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-3-propyl-1H-pyrrole-2-carboxamide,

3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-5-(3-methylbenzoyl)-1H-pyrrole-2-carboxamide,

5-(2,3-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-3-propyl-1H-pyrrole-2-carboxamide,

5-(2,6-difluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-5-(2-methylbenzoyl)-1H-pyrrole-2-carboxamide,

5-(3-chlorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-[3-(difluoromethoxy)benzoyl]-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-3-propyl-1H-pyrrole-2-carboxamide,

5-(3-cyanobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-5-[(5-methyl-2-thienyl)carbonyl]-1H-pyrrole-2-carboxamide,

5-[2-(difluoromethyl)benzoyl]-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(3-fluoro-5-methoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-cyclopropyl-5-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(2,4-difluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(4-fluoro-3-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-benzoyl-N-[(E)-5-hydroxyadamantan-2-yl]-3-isopropyl-1-methyl-1H-pyrrole-2-carboxamide,

5-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-3-isopropyl-1-methyl-1H-pyrrole-2-carboxamide,

5-(3-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-3-isopropyl-1-methyl-1H-pyrrole-2-carboxamide,

5-(2,6-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-3-isopropyl-1-methyl-1H-pyrrole-2-carboxamide,

5-(3,5-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(3,5-difluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(2-fluoro-5-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(4-fluoro-3-methoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-5-[3-(trifluoromethoxy)benzoyl]-1H-pyrrole-2-carboxamide,

5-(4-cyanobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(3,4-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(3,4-difluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-[4-fluoro-3-(trifluoromethoxy)benzoyl]-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(2-fluoro-5-methoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-[2-fluoro-3-(trifluoromethoxy)benzoyl]-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(5-ethoxy-2-fluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(3-ethoxy-5-fluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(3-fluoro-5-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(3-fluoro-5-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-benzoyl-3-cyclopropyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-cyclopropyl-5-(3-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

3-cyclopropyl-5-(2,6-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(3-fluoro-5-methoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(4-fluoro-3-methoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(3-ethoxy-4-fluorobenzoyl)-3-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide,

5-(3-ethoxy-4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

5-(4-fluoro-3-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide,

3-ethyl-5-(3-ethylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1-methyl-1H-pyrrole-2-carboxamide, and

5-(3-ethylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-1,3-dimethyl-1H-pyrrole-2-carboxamide.

28. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the following compound group:

2-chloro-4-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

2-chloro-4-(2,4-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-4-(2-methylbenzoyl)benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-4-(3-methylbenzoyl)benzamide,

4-(2-chlorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)benzamide,

4-(2,4-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-methoxybenzamide,

4-(4-ethoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)benzamide],

2-(ethoxymethyl)-4-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

2-ethoxy-4-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide,

2-ethyl-4-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

2-ethyl-4-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-(3-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide,

4-(4-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide,

4-(2,3-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)benzamide,

4-(2,5-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)benzamide,

4-(2-fluoro-3-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-benzamide,

4-(2-fluoro-5-methoxybenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-benzamide,

4-(2-fluoro-5-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-benzamide,

2-cyclopropyl-4-(2-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-[2-(difluoromethyl)benzoyl]-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-benzamide,

4-(3-fluoro-2-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-benzamide,

4-(5-fluoro-2-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-benzamide,

4-(2,4-difluorobenzoyl)-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-benzoyl-N-[(E)-5-hydroxyadamantan-2-yl]-2-(2-methoxyethyl)benzamide,

4-(3-fluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-(2-methoxyethyl)benzamide,

4-[2-(difluoromethyl)benzoyl]-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-benzoyl-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide,

4-benzoyl-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-(2,4-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide,

4-[3-(difluoromethyl)benzoyl]-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

2-ethyl-4-(2-fluoro-3-methylbenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-(3,4-difluorobenzoyl)-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-(3,5-difluorobenzoyl)-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide, and

4-(2,6-difluorobenzoyl)-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide.

29. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the following compound group:

2-chloro-N-[(E)-5-hydroxyadamantan-2-yl]-4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-methoxy-4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-4-[(1-methyl-1H-pyrrol-2-yl)-carbonyl]benzamide,

4-[(1-ethyl-1H-pyrrol-2-yl)carbonyl]-N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-4-(2-pyridinylcarbonyl)benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-4-(1,3-thiazol-2-ylcarbonyl)benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-4-{[1-(2-methoxyethyl)-1H-pyrrol-2-yl]carbonyl}-2-(methoxymethyl)benzamide,

2-ethyl-4-[(1-ethyl-1H-pyrrol-2-yl)carbonyl]-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-(methoxymethyl)-4-[(1-methyl-1H-pyrazol-5-yl)-carbonyl]benzamide,

2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-4-[(1-methyl-pyrazol-5-yl)carbonyl]benzamide,

2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-4-(2-pyridinylcarbonyl)benzamide,

2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-4-[(3-methyl-2-pyridinyl)carbonyl]benzamide,

2-ethyl-4-[(3-fluoro-2-pyridinyl)carbonyl]-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

4-[(3-chloro-2-pyridinyl)carbonyl]-2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

2-ethyl-N-[(E)-5-hydroxyadamantan-2-yl]-4-[(4-methyl-2-pyridinyl)carbonyl]benzamide,

2-ethyl-4-[(5-fluoro-2-pyridinyl)carbonyl]-N-[(E)-5-hydroxyadamantan-2-yl]benzamide,

N-[(E)-5-hydroxyadamantan-2-yl]-2-propyl-4-(2-pyridinylcarbonyl)benzamide,

4-[(3-fluoro-2-pyridinyl)carbonyl]-N-[(E)-5-hydroxyadamantan-2-yl]-2-propylbenzamide, and

4-[(3-fluoro-2-pyridinyl)carbonyl]-N-[(E)-5-hydroxyadamantan-2-yl]-2-methylbenzamide.

30. A pharmaceutical composition, which comprises the compound of claim 1 or a pharmaceutically acceptable salt thereof.

31. A therapeutic agent for type II diabetes, abnormal glucose tolerance, hyperglycemia, insulin resistance, dyslipidemia, hypertension, arteriosclerosis, angiostenosis, obesity, Cushing syndrome, subclinical Cushing syndrome, glaucoma, osteoporosis, metabolic syndrome, cardiovascular disease, atherosclerosis, cognitive disorder, dementia, Alzheimer's disease, depression, anxiety or manic depression, which comprises as the active ingredient the compound of claim 1 or a pharmaceutically acceptable salt thereof.

32. A method for treating type II diabetes, abnormal glucose tolerance, hyperglycemia, insulin resistance, dyslipidemia, hypertension, arteriosclerosis, angiostenosis, obesity, Cushing syndrome, subclinical Cushing syndrome, glaucoma, osteoporosis, metabolic syndrome, cardiovascular disease, atherosclerosis, cognitive disorder, dementia, Alzheimer's disease, depression, anxiety or manic depression, comprising as the active ingredient the compound of claim 1 or a pharmaceutically acceptable salt thereof.